News & Media

Recent updates from Arcutis.

July 1, 2021

Arcutis Provides Update on Phase 2a Clinical Trial Evaluating ARQ-252 Cream as a Potential Treatment for Vitiligo

June 23, 2021

Greg Sukay Joins Arcutis as Vice President of Manufacturing and Process Technologies

June 9, 2021

Arcutis Announces Appointment of Sue-Jean Lin to Board of Directors

June 1, 2021

Rajvir Madan Joins Arcutis as Chief Digital and Information Officer

May 6, 2021

Arcutis Biotherapeutics Showcases Pivotal DERMIS-1 and -2 Phase 3 Trial Data for Topical Roflumilast Cream (ARQ-151) in Plaque Psoriasis at EADV Spring Symposium 2021

May 4, 2021

Arcutis Announces First Quarter 2021 Financial Results and Provides Business Update

May 3, 2021

Arcutis to Present New Roflumilast Cream Phase 3 Data at The European Academy of Dermatology and Venereology (EADV) Spring Symposium

April 28, 2021

Arcutis to Present at the 2021 Truist Securities Life Sciences Summit

April 23, 2021

Arcutis Biotherapeutics Showcases New Roflumilast Data in Psoriasis and Seborrheic Dermatitis at American Academy of Dermatology (AAD) Virtual Meeting Experience (VMX) 2021

April 19, 2021

Arcutis Biotherapeutics to Present New Roflumilast Data at The American Academy of Dermatology (AAD) Virtual Meeting Experience (VMX)

April 12, 2021

Arcutis Initiates Phase 3 Clinical Trial of Topical Roflumilast Cream (ARQ-151) as a Potential Treatment for Atopic Dermatitis in Pediatric Patients Between the Ages of Two and Five Years

March 26, 2021

Arcutis Announces Updates to its Executive Team

Media Resources

Corporate Fact Sheet

Uncovering Psoriasis

Journal of the American Medical Association Roflumilast Cream 0.3% Result

Media Contact

Amanda Sheldon

805.418.5006
media@arcutis.com

Meaningful innovation at a glance.

Download our corporate fact sheet.

Download